8-K Announcements
6Material company update
Mar 17, 2026·SEC
Material company update
Feb 23, 2026·SEC
Material company update
Feb 19, 2026·SEC
Mangoceuticals, Inc.(MGRX)Earnings, Financials & Key Ratios
MGRX•NASDAQ
$0.37
Price updated Jul 7, 2026
AboutMangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.Show more
- Revenue$456K-26.0%
- EBITDA-$17M-140.4%
- Net Income-$21M-137.1%
- EPS (Diluted)-2.05+53.4%
- Gross Margin54.91%-11.0%
- EBITDA Margin-3822.36%-224.7%
- Operating Margin-4200.46%-224.5%
- Net Margin-4526.86%-220.2%
- ROE-141.66%-19.8%
MGRX Price & Volume
Mangoceuticals, Inc. (MGRX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Threatens Operational Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Existential liquidity and solvency
Key Thesis Takeaways
- Mangoceuticals faces an existential liquidity crisis characterized by a 25.96% year-over-year revenue decline and deeply negative operating margins that reached -46.1% in 2026Q1.
- The company's reliance on intangible goodwill, which comprises 96% of total assets, combined with a rapidly deteriorating current ratio of 0.29, suggests significant long-term financial instability.
- Investors should remain cautious as the firm struggles to convert its direct-to-consumer telemedicine model into a self-sustaining, cash-generative business.
Verdict Logic
the company's precarious liquidity position, highlighted by a cash balance of only $174.6K against a $3.4M net loss in 2026Q1, indicates an unsustainable path forward for shareholders.
MGRX Growth Metrics
Mangoceuticals, Inc. (MGRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years270.88%
TTM-18.88%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-71.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM56.23%
Return on Capital
10 Years-488.28%
5 Years-488.28%
3 Years-468.15%
Last Year-131.45%
MGRX Recent Earnings
Mangoceuticals, Inc. (MGRX) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 19, 2026Metric
Actual
Est
EPS
$0.22
—
Rev
$67,864
—
Q2 2026
Apr 1, 2026Metric
Actual
Est
EPS
$0.13
—
Rev
$94,360
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.69
—
Rev
$84,246
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.57
—
Rev
$168,109
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 19, 2026 | $0.22 | $67,864 |
| Q2 2026 | Apr 1, 2026 | $0.13 | $94,360 |
| Q4 2025 | Nov 14, 2025 | $0.69 | $84,246 |
| Q3 2025 | Aug 14, 2025 | $0.57 | $168,109 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Mangoceuticals, Inc. (MGRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.37 | $3.78M | -0.18 | -25.96% | -4526.86% | -141.66% | — | |
| $36.17 | $7.94B | 70.92 | 59% | -0.56% | -2.48% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $8.99 | $150.21M | -1.51 | -1.98% | -48.16% | -33.48% | — | |
| $9.10 | $1.64B | -7.98 | -1.54% | -6.81% | -12.37% | — | |
| $6.29 | $118.03M | 23.30 | 18.78% | 6.37% | 5.47% | — |
Compare MGRX vs Peers
Mangoceuticals, Inc. (MGRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MGRX SEC Filings & Documents
Mangoceuticals, Inc. (MGRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when MGRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MGRX Frequently Asked Questions
Mangoceuticals, Inc. (MGRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Mangoceuticals, Inc.'s revenue?
Mangoceuticals, Inc. (MGRX) reported $0.4M in revenue for fiscal year 2025.
How fast is Mangoceuticals, Inc. growing?
Mangoceuticals, Inc. (MGRX) saw revenue decline by 26.0% over the past year.
Is MGRX profitable?
Mangoceuticals, Inc. (MGRX) reported a net loss of $19.2M for fiscal year 2025.
Dividend & Returns
What is MGRX's return on equity?
Mangoceuticals, Inc. (MGRX) has a return on equity (ROE) of -141.7%. Negative ROE indicates the company is unprofitable.
What is Mangoceuticals, Inc.'s free cash flow?
Mangoceuticals, Inc. (MGRX) had negative free cash flow of $4.9M in fiscal year 2025, likely due to heavy capital investments.